12/16
09:08 am
nams
Menarini Group announces Positive Topline Data from Pivotal Phase 3 BROADWAY & TANDEM Clinical Trials Evaluating Obicetrapib and the Fixed-Dose Combination Obicetrapib with Ezetimibe 10 mg
Medium
Report
Menarini Group announces Positive Topline Data from Pivotal Phase 3 BROADWAY & TANDEM Clinical Trials Evaluating Obicetrapib and the Fixed-Dose Combination Obicetrapib with Ezetimibe 10 mg
12/16
08:43 am
nams
Menarini Group announces Positive Topline Data from Pivotal Phase 3 BROADWAY & TANDEM Clinical Trials Evaluating Obicetrapib and the Fixed-Dose Combination Obicetrapib with Ezetimibe 10 mg
Low
Report
Menarini Group announces Positive Topline Data from Pivotal Phase 3 BROADWAY & TANDEM Clinical Trials Evaluating Obicetrapib and the Fixed-Dose Combination Obicetrapib with Ezetimibe 10 mg
12/16
08:40 am
nams
Menarini Group announces Positive Topline Data from Pivotal Phase 3 BROADWAY & TANDEM Clinical Trials Evaluating Obicetrapib and the Fixed-Dose Combination Obicetrapib with Ezetimibe 10 mg
Low
Report
Menarini Group announces Positive Topline Data from Pivotal Phase 3 BROADWAY & TANDEM Clinical Trials Evaluating Obicetrapib and the Fixed-Dose Combination Obicetrapib with Ezetimibe 10 mg
12/13
05:20 pm
nams
NewAmsterdam Pharma Announces Closing of Upsized $479.0 Million Public Offering of Ordinary Shares and Pre-Funded Warrants, Including Full Exercise of the Underwriters' Option to Purchase Additional Shares [Yahoo! Finance]
Medium
Report
NewAmsterdam Pharma Announces Closing of Upsized $479.0 Million Public Offering of Ordinary Shares and Pre-Funded Warrants, Including Full Exercise of the Underwriters' Option to Purchase Additional Shares [Yahoo! Finance]
12/13
05:16 pm
nams
NewAmsterdam Pharma Announces Closing of Upsized $479.0 Million Public Offering of Ordinary Shares and Pre-Funded Warrants, Including Full Exercise of the Underwriters’ Option to Purchase Additional Shares
Low
Report
NewAmsterdam Pharma Announces Closing of Upsized $479.0 Million Public Offering of Ordinary Shares and Pre-Funded Warrants, Including Full Exercise of the Underwriters’ Option to Purchase Additional Shares
12/11
09:41 pm
nams
NewAmsterdam Pharma Announces Pricing of Upsized $416.5 Million Public Offering of Ordinary Shares and Pre-Funded Warrants [Yahoo! Finance]
Low
Report
NewAmsterdam Pharma Announces Pricing of Upsized $416.5 Million Public Offering of Ordinary Shares and Pre-Funded Warrants [Yahoo! Finance]
12/11
09:37 pm
nams
NewAmsterdam Pharma Announces Pricing of Upsized $416.5 Million Public Offering of Ordinary Shares and Pre-Funded Warrants
Low
Report
NewAmsterdam Pharma Announces Pricing of Upsized $416.5 Million Public Offering of Ordinary Shares and Pre-Funded Warrants
12/11
11:12 am
nams
NewAmsterdam Pharma (NASDAQ: NAMS) had its price target raised by analysts at Scotiabank from $35.00 to $47.00. They now have a "sector outperform" rating on the stock.
Medium
Report
NewAmsterdam Pharma (NASDAQ: NAMS) had its price target raised by analysts at Scotiabank from $35.00 to $47.00. They now have a "sector outperform" rating on the stock.
12/10
04:34 pm
nams
NewAmsterdam Pharma Announces Commencement of $300 Million Public Offering of Ordinary Shares and Pre-Funded Warrants
Low
Report
NewAmsterdam Pharma Announces Commencement of $300 Million Public Offering of Ordinary Shares and Pre-Funded Warrants
12/10
11:17 am
nams
Why Is NewAmsterdam Pharma Stock Trading Higher On Tuesday? [Yahoo! Finance]
Medium
Report
Why Is NewAmsterdam Pharma Stock Trading Higher On Tuesday? [Yahoo! Finance]
12/10
07:07 am
nams
NewAmsterdam Pharma Announces Positive Topline Data from Pivotal Phase 3 BROADWAY Clinical Trial Evaluating Obicetrapib in Patients with Atherosclerotic Cardiovascular Disease and/or Heterozygous Familial Hypercholesterolemia [Yahoo! Finance]
High
Report
NewAmsterdam Pharma Announces Positive Topline Data from Pivotal Phase 3 BROADWAY Clinical Trial Evaluating Obicetrapib in Patients with Atherosclerotic Cardiovascular Disease and/or Heterozygous Familial Hypercholesterolemia [Yahoo! Finance]
12/10
07:00 am
nams
NewAmsterdam Pharma Announces Positive Topline Data from Pivotal Phase 3 BROADWAY Clinical Trial Evaluating Obicetrapib in Patients with Atherosclerotic Cardiovascular Disease and/or Heterozygous Familial Hypercholesterolemia
High
Report
NewAmsterdam Pharma Announces Positive Topline Data from Pivotal Phase 3 BROADWAY Clinical Trial Evaluating Obicetrapib in Patients with Atherosclerotic Cardiovascular Disease and/or Heterozygous Familial Hypercholesterolemia
12/6
04:01 pm
nams
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Low
Report
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
12/5
08:01 am
nams
NewAmsterdam Pharma (NASDAQ: NAMS) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $36.00 price target on the stock.
Medium
Report
NewAmsterdam Pharma (NASDAQ: NAMS) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $36.00 price target on the stock.
11/21
08:05 am
nams
NewAmsterdam Pharma (NASDAQ: NAMS) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $36.00 price target on the stock.
Low
Report
NewAmsterdam Pharma (NASDAQ: NAMS) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $36.00 price target on the stock.
11/20
07:07 am
nams
NewAmsterdam Pharma Announces Positive Topline Data from Pivotal Phase 3 TANDEM Clinical Trial Evaluating the Fixed-Dose Combination of Obicetrapib 10 mg and Ezetimibe 10 mg in Patients with ASCVD or ASCVD Risk Factors and/or HeFH [Yahoo! Finance]
High
Report
NewAmsterdam Pharma Announces Positive Topline Data from Pivotal Phase 3 TANDEM Clinical Trial Evaluating the Fixed-Dose Combination of Obicetrapib 10 mg and Ezetimibe 10 mg in Patients with ASCVD or ASCVD Risk Factors and/or HeFH [Yahoo! Finance]
11/20
07:00 am
nams
NewAmsterdam Pharma Announces Positive Topline Data from Pivotal Phase 3 TANDEM Clinical Trial Evaluating the Fixed-Dose Combination of Obicetrapib 10 mg and Ezetimibe 10 mg in Patients with ASCVD or ASCVD Risk Factors and/or HeFH
High
Report
NewAmsterdam Pharma Announces Positive Topline Data from Pivotal Phase 3 TANDEM Clinical Trial Evaluating the Fixed-Dose Combination of Obicetrapib 10 mg and Ezetimibe 10 mg in Patients with ASCVD or ASCVD Risk Factors and/or HeFH
11/19
08:00 am
nams
Frazier Life Sciences Appoints John Smither and Jim Williams as Senior Advisors
Medium
Report
Frazier Life Sciences Appoints John Smither and Jim Williams as Senior Advisors
11/18
03:26 pm
nams
NewAmsterdam Pharma Presents Additional Data from Pivotal Phase 3 BROOKLYN Clinical Trial Evaluating Obicetrapib in Patients with Heterozygous Familial Hypercholesterolemia at AHA Scientific Sessions 2024 [Yahoo! Finance]
Low
Report
NewAmsterdam Pharma Presents Additional Data from Pivotal Phase 3 BROOKLYN Clinical Trial Evaluating Obicetrapib in Patients with Heterozygous Familial Hypercholesterolemia at AHA Scientific Sessions 2024 [Yahoo! Finance]
11/18
03:20 pm
nams
NewAmsterdam Pharma Presents Additional Data from Pivotal Phase 3 BROOKLYN Clinical Trial Evaluating Obicetrapib in Patients with Heterozygous Familial Hypercholesterolemia at AHA Scientific Sessions 2024
Low
Report
NewAmsterdam Pharma Presents Additional Data from Pivotal Phase 3 BROOKLYN Clinical Trial Evaluating Obicetrapib in Patients with Heterozygous Familial Hypercholesterolemia at AHA Scientific Sessions 2024
11/11
06:14 am
nams
NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) Shares Could Be 46% Below Their Intrinsic Value Estimate [Yahoo! Finance]
Low
Report
NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) Shares Could Be 46% Below Their Intrinsic Value Estimate [Yahoo! Finance]
11/7
08:36 am
nams
NewAmsterdam Pharma (NASDAQ: NAMS) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $36.00 price target on the stock.
Medium
Report
NewAmsterdam Pharma (NASDAQ: NAMS) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $36.00 price target on the stock.
11/6
08:00 am
nams
NewAmsterdam Pharma Provides Corporate Update and Reports Third Quarter Financial Results
High
Report
NewAmsterdam Pharma Provides Corporate Update and Reports Third Quarter Financial Results
11/1
05:26 pm
nams
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Medium
Report
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
10/28
04:30 pm
nams
NewAmsterdam Pharma to Participate in Upcoming Medical and Investor Conferences in November
Low
Report
NewAmsterdam Pharma to Participate in Upcoming Medical and Investor Conferences in November